Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer

J Clin Oncol. 2011 Jul 1;29(19):e572-5. doi: 10.1200/JCO.2010.34.0604. Epub 2011 Apr 11.
No abstract available

Publication types

  • Case Reports
  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Breast Neoplasms / drug therapy*
  • Carcinoma / drug therapy*
  • Doxorubicin / administration & dosage*
  • Female
  • Humans
  • Metaplasia / pathology
  • Middle Aged
  • Neoplasm Metastasis
  • Prognosis
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / biosynthesis
  • Receptors, Progesterone / biosynthesis
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives*
  • Stem Cell Transplantation / trends
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Bevacizumab
  • temsirolimus
  • Doxorubicin
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Sirolimus